Evaluation of the Efficacy of STRATAFIX for Neurosurgical Cranial and Spine Procedures

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Michigan

About this trial

This research is studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Elective or emergent surgical approaches for cranial or spine neurosurgical approaches, requiring sutures for wound closure, requiring multilayer wound closure

Disqualifiers

Patients with prior surgical wound dehiscence or infection

Patients with allergy to suture material

Trial design

Design model

Single group

Treatments tested in this trial

  • STRATAFIX PDS and Monocryl suture

    Device

    STRATAFIX, suture employs a novel incorporation of barbed components to suture resulting in tension holding closure with long-lasting absorbable suture.

Treatment groups

160 Participants
are divided into 1 treatment group
Group A: STRATAFIX PDS and Monocryl sutureExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Wound complications Bates-Jensen Wound Assessment Tool (BWAT) score

The BWAT evaluates 13 categories including size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, skin color, peripheral tissue, granulation tissue and epithelialization with a total score of 65. Minimal severity scores are 10-20 out of the total of 65 with good interrater reliability and validation in a variety of clinical environments. Wounds with scores \<10 will be considered healed.

Time frame
1 month

Secondary outcomes

1

Wound complications Bates-Jensen Wound Assessment Tool (BWAT) score

The BWAT evaluates 13 categories including size, depth, edges, undermining, necrotic tissue type and amount, exudate type and amount, skin color, peripheral tissue, granulation tissue and epithelialization with a total score of 65. Minimal severity scores are 10-20 out of the total of 65 with good interrater reliability and validation in a variety of clinical environments. Wounds with scores \<10 will be considered healed. Scores will be separated into specific patient subgroups (e.g., spine procedures vs. cranial procedures, younger vs. older patients)

Time frame
3 and 6 months
2

The Wound-Quality of Life (QOL) questionnaire score

This is a 17-point scale with 5 choices each ranging from 17-85. Higher scores indicate worse quality of life.

Time frame
1, 3 and 6 months
3

Intraoperative time required for wound closure

Time for intraoperative wound closure will be monitored. Wound closure technique will be video recorded.

Time frame
Immediately following surgery
4

Percent of participants positive for superficial surgical site infection (SSI)

Assessed using a culture or polymerase chain reaction

Time frame
Up to six months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Michigan

Lead sponsor

Johnson & Johnson

Collaborator